Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

RNA-Based Drugs Give More Control Over Gene Editing

By Drug Discovery Trends Editor | November 17, 2015

In just the past few years, researchers have found a way to use a naturally occurring bacterial system known as CRISPR/Cas9 to inactivate or correct specific genes in any organism. CRISPR/Cas9 gene editing activity runs continuously, though, leading to risk of additional editing at unwanted sites. Now, researchers at University of California, San Diego School of Medicine, Ludwig Cancer Research and Isis Pharmaceuticals demonstrate a commercially feasible way to use RNA to turn the CRISPR-Cas9 system on and off as desired — permanently editing a gene, but only temporarily activating CRISPR-Cas9. The study is published November 16 by Proceedings of the National Academy of Sciences.
 
“These findings provide a platform for multiple therapeutic applications, especially for nervous system diseases, using successive application of designer CRISPR RNA drugs,” said senior author Don Cleveland, PhD, Distinguished Professor and Chair of the Department of Cellular and Molecular Medicine at UC San Diego School of Medicine and head of Ludwig Cancer Research’s Laboratory for Cell Biology.
 
CRISPR/Cas9 works like this: researchers design a “guide” RNA to match the sequence of a specific target gene. The RNA guides the Cas9 enzyme to the desired spot, where it cuts the DNA. The cell can repair the DNA break, but it does so imprecisely, thereby inactivating the gene. Alternatively, researchers can coax the cell into replacing the section adjacent to the cut with a healthier version of the gene. Researchers are now testing the CRISPR/Cas9 system in a variety of applications to repair defective genes that cause disease.
 
The new approach introduces chemically modified, RNA-based drugs to transiently activate the CRISPR/Cas9 gene editing system. An initial, specially modified RNA is used to replace the usual guide RNA. This RNA directs Cas9’s DNA-cutting activity to a selected target gene and the editing process proceeds. Activity is transient, however, as the editing stops when the guiding RNA drug is cleared. An extension of the approach can switch off the molecular scissors even faster by addition of a second, chemically modified RNA drug that directs inactivation of the gene encoding the Cas9 enzyme. 
 
“The RNA-based drugs we developed in this study provide many advantages over the current CRISPR/Cas9 system, such as increased editing efficiency and potential selectivity,” said Cleveland. “In addition, they can be synthesized efficiently, on an industrial scale and in a commercially feasible manner today.” 
 
“Today’s published work is another demonstration of the successful synergy between Dr. Cleveland’s lab and my team at Isis Pharmaceuticals,” said C. Frank Bennet, PhD, co-senior author of the study and senior vice president of research at Isis Pharmaceuticals. “Leveraging Isis’ expertise in developing RNA-targeted compounds, together the team has demonstrated that we can develop molecules that enhance the effectiveness of the CRISPR mechanism.”
 
Study co-authors include Meghdad Rahdar, Thazha P. Prakash, Eric E. Swayze, Isis Pharmaceuticals; Moira A. McMahon, Ludwig Cancer Research and UC San Diego. 
 
This research was funded, in part, by the National Institutes of Health (grants R01-GM 074150, R01-NS27036 and F32-GM109657). Cleveland is a paid consultant of Isis Pharmaceuticals.
 
Source: UC San Diego

Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
A media release and Scientific Report image of Elizabeth Kellogg. - Camera Settings: ILCE-9M2, 12mm, ISO 1000, 1/80, f/3.2, Fri, 04-19-2024 at 10:10. v.12.01.23
St. Jude pioneers gene editing and structural biology to advance pediatric research
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE